Kosmetische Medizin 2-2011: 76-79

5 YEARS OF ETANERCEPT INTERMITTENT LONG-TERM THERAPY OF PSORIASIS VULGARIS WITHOUT LOSS OF EFFICACY

BERND KARDORFF 1, 2, IRENE STERGIOU1, PETER DORITTKE 1, 2

1 Gemeinschaftspraxis für Dermatologie, Venerologie, Phlebologie, Allergologie,
Umweltmedizin, Ambulante Operationen und Lasertherapie
Dres. Dorittke und Kardorff, D-41236 Mönchengladbach-Rheydt
2 Haut-, Allergie- und Venenpraxis, D-41352 Korschenbroich

KEY WORDS: Psoriasis, biologics, Etanercept, intermittent long-term therapy

SUMMARY:
Plaque Psoriasis is a chronic, relapsing inflammatory disease with a certain need for flexible therapy. In addition, several events like infections, surgery, pregnancy, accidents but also the patient’s desire for a drug holiday may occur. Therefore a modern biologic therapy should work in a continuous and in an intermittent long-term treatment as well. The TNF receptor Etanercept is different to the registered TNF antibodies in that there is no evidence for neutralising antibodies against Etanercept. Clinical trials show that a re-treatment with Etanercept after a drug free interval will lead to similar results. Here we report a case of a patient that was treated intermittently with Etanercept for 5 years.

[download id=”245″ format=”3″]